Bayer calms break-up speculation as Crop Science drives earnings beat

Bayer reported strong second-quarter results, led by its Crop Science division, which saw robust sales and profitability, helping the company beat earnings expectations. CEO Bill Anderson dismissed speculation about breaking up the company, emphasizing a focus on five strategic priorities, including improving the pharma pipeline, increasing Crop Science profitability, reducing debt, resolving litigation, and boosting productivity. Progress in resolving glyphosate litigation and a €3bn investment from Apollo have improved Bayer’s balance sheet and outlook. Management believes that operational improvements and addressing key challenges are the best path to unlocking value, rather than pursuing a breakup at this stage.